Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2019
Reporting Period: Events occurring between January 10, 2019, and January 28, 2019.
Item Reported: Item 3.02 Unregistered Sales of Equity Securities.
Key Financial Metrics and Capital Structure Changes
This filing details specific financing activities rather than standard operating financial metrics (revenue, profit, cash flow). Key capital structure changes include:
- Convertible Notes Issued: Aggregate principal of $940,000 for net cash proceeds of $846,638.
- Debt Prepayment: $579,655 of the new proceeds were used to prepay outstanding convertible notes.
- Debt-for-Equity Exchange: 413,633 shares of common stock issued to settle $125,530 of outstanding indebtedness (including accrued interest and fees).
- Warrant Issuance: One warrant issued for 40,000 shares at an exercise price of $1.00 per share.
- Interest Rate: New notes bear interest at 12% per annum.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against a prior period. The material change reported is the execution of new debt financing and the conversion of existing debt into equity during the first three weeks of January 2019.
Terms, Risks, and Management Commentary
Convertible Note Terms:
- Maturity: Ranges between July 2019 and January 2020.
- Conversion Mechanics:
- $280,000 principal: Convertible at $1.00/share for the first six months; thereafter at 58% of fair value.
- $45,000 principal: Convertible after 180 days at 58% of fair market value.
- $615,000 principal: Convertible after 180 days at the lesser of 58% of fair value or $0.69 per share.
Regulatory Basis: Transactions relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933. No general solicitation was used, and the Company believes all investors are accredited.
Risks/Contingencies: The filing does not explicitly list new risks, though the issuance of convertible notes with significant discounts (58% of fair value) and fixed low conversion prices ($0.69) implies potential future dilution for existing shareholders.
Investor Verification Checklist
- Verify the current fair market value of the Company's common stock to assess the dilution impact of the 58% conversion discount.
- Confirm the total outstanding debt balance after the $579,655 prepayment and the $125,530 debt-for-equity exchange.
- Review the Company's cash position to determine if the $846,638 in net proceeds is sufficient to meet operational needs until the note maturities (July 2019–January 2020).
- Check subsequent filings for any further conversions of the $940,000 in new notes or the exercise of the 40,000-share warrant.